Consequently, we suggest that the MSC-like properties of CD133+ glioblastoma-initiating cells confer pro-angiogenic, anti-apoptotic and immunomodulatory characteristics that may sustain tumor growth even in animals that are not immunocompromised. Here, PROM1 is linked to glioblastoma.